HRP20110844T1 - Tekući oblici soli 4-[2-(4-metilfenilsulfanil)fenil]piperidina - Google Patents
Tekući oblici soli 4-[2-(4-metilfenilsulfanil)fenil]piperidina Download PDFInfo
- Publication number
- HRP20110844T1 HRP20110844T1 HR20110844T HRP20110844T HRP20110844T1 HR P20110844 T1 HRP20110844 T1 HR P20110844T1 HR 20110844 T HR20110844 T HR 20110844T HR P20110844 T HRP20110844 T HR P20110844T HR P20110844 T1 HRP20110844 T1 HR P20110844T1
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- addition salt
- disorder
- methylphenylsulfanyl
- phenyl
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract 34
- CVASBKDYSQKLSO-UHFFFAOYSA-N Tedatioxetine Chemical class C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 CVASBKDYSQKLSO-UHFFFAOYSA-N 0.000 title claims abstract 5
- 239000012669 liquid formulation Substances 0.000 title 1
- 239000007788 liquid Substances 0.000 claims abstract 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract 5
- 235000013922 glutamic acid Nutrition 0.000 claims abstract 5
- 239000004220 glutamic acid Substances 0.000 claims abstract 5
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims abstract 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 4
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960005261 aspartic acid Drugs 0.000 claims abstract 4
- 229960000448 lactic acid Drugs 0.000 claims abstract 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims abstract 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims abstract 3
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- IRVVYGZWADUSLH-WNQIDUERSA-N (2s)-2-aminobutanedioic acid;4-[2-(4-methylphenyl)sulfanylphenyl]piperidine Chemical compound OC(=O)[C@@H](N)CC(O)=O.C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 IRVVYGZWADUSLH-WNQIDUERSA-N 0.000 claims 1
- XTFKXTIIMDHGOP-UHFFFAOYSA-N 2-hydroxypropanoic acid;4-[2-(4-methylphenyl)sulfanylphenyl]piperidine Chemical compound CC(O)C(O)=O.C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 XTFKXTIIMDHGOP-UHFFFAOYSA-N 0.000 claims 1
- BDYBPDKXGILWKO-UHFFFAOYSA-N 4-[2-(4-methylphenyl)sulfanylphenyl]piperidine;pentanedioic acid Chemical compound OC(=O)CCCC(O)=O.C1=CC(C)=CC=C1SC1=CC=CC=C1C1CCNCC1 BDYBPDKXGILWKO-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000027691 Conduct disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 201000003995 melancholia Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200700423 | 2007-03-20 | ||
| PCT/DK2007/050076 WO2007144006A1 (fr) | 2006-06-16 | 2007-06-15 | Formes cristallines de la 4-[2-(4-méthylphénylsulfanyl)-phényl] pipéridine avec inhibition de la réabsorption de la sérotonine et de la norépinéphrine en combinaison pour le traitement de la douleur neuropathique |
| US1391807P | 2007-12-14 | 2007-12-14 | |
| DKPA200701790 | 2007-12-14 | ||
| PCT/DK2008/050062 WO2008113358A1 (fr) | 2007-03-20 | 2008-03-14 | Formulations liquides de sels de 4-[2-4-méthylphénylsulfanyl)phényl]pipéridine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110844T1 true HRP20110844T1 (hr) | 2011-12-31 |
Family
ID=39327217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110844T HRP20110844T1 (hr) | 2007-03-20 | 2011-11-14 | Tekući oblici soli 4-[2-(4-metilfenilsulfanil)fenil]piperidina |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20100105730A1 (fr) |
| EP (2) | EP2388004A1 (fr) |
| JP (1) | JP5301474B2 (fr) |
| KR (1) | KR20090130000A (fr) |
| AR (1) | AR065796A1 (fr) |
| AT (1) | ATE526966T1 (fr) |
| AU (1) | AU2008228637B2 (fr) |
| BR (1) | BRPI0808820A2 (fr) |
| CA (1) | CA2684592C (fr) |
| CL (1) | CL2008000797A1 (fr) |
| CO (1) | CO6220958A2 (fr) |
| CY (1) | CY1112285T1 (fr) |
| DK (1) | DK2129377T3 (fr) |
| EA (1) | EA019695B1 (fr) |
| ES (1) | ES2373275T3 (fr) |
| HK (1) | HK1140949A1 (fr) |
| HR (1) | HRP20110844T1 (fr) |
| IL (1) | IL200959A (fr) |
| MX (1) | MX2009009388A (fr) |
| MY (1) | MY148695A (fr) |
| NZ (1) | NZ579717A (fr) |
| PL (1) | PL2129377T3 (fr) |
| PT (1) | PT2129377E (fr) |
| RS (1) | RS52050B (fr) |
| SI (1) | SI2129377T1 (fr) |
| TW (1) | TWI405588B (fr) |
| WO (1) | WO2008113358A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI432194B (zh) | 2007-03-20 | 2014-04-01 | Lundbeck & Co As H | ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途 |
| SI2167085T1 (sl) * | 2007-06-15 | 2014-05-30 | H. Lundbeck A/S | 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs) |
| KR101779214B1 (ko) * | 2009-04-24 | 2017-09-18 | 하. 룬드벡 아크티에셀스카브 | １―［２―（２，４―디메틸페닐술파닐）페닐］피페라진 염의 액체 제형 |
| JP5787881B2 (ja) | 2010-04-30 | 2015-09-30 | 武田薬品工業株式会社 | 腸溶性錠剤 |
| CN102970982B (zh) | 2010-04-30 | 2015-01-14 | 武田药品工业株式会社 | 肠溶片剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10163326A1 (de) * | 2001-07-30 | 2003-02-27 | Disetronic Licensing Ag | Verabreichungsgerät mit Dosiervorrichtung |
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| EP1446328B1 (fr) | 2001-10-16 | 2017-05-31 | Medical Instill Technologies, Inc. | DISTRIBUTEUR PRESENTANT UNE CHAMBRE ETANCHE ET UNE VALVE ANTI−REFLUX PERMETTANT D ADMINISTRER DES DOSES MESUREES DE SUB STANCES |
| DE10202367A1 (de) | 2002-01-23 | 2003-09-25 | Duerr Dental Gmbh Co Kg | Applikator für flüssige oder viskose Substanzen |
| JP4667366B2 (ja) * | 2003-04-04 | 2011-04-13 | ハー・ルンドベック・アクチエゼルスカベット | セロトニン再取り込み阻害剤としての４−（２−フェニルスルファニル−フェニル）−ピペリジン誘導体 |
| EA016054B1 (ru) * | 2006-06-16 | 2012-01-30 | Х. Лундбекк А/С | Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли |
| KR101367136B1 (ko) * | 2007-07-27 | 2014-02-25 | 삼성디스플레이 주식회사 | 유기 발광 표시 장치 및 이의 제조 방법 |
-
2008
- 2008-03-06 TW TW097107758A patent/TWI405588B/zh not_active IP Right Cessation
- 2008-03-14 RS RS20110545A patent/RS52050B/en unknown
- 2008-03-14 WO PCT/DK2008/050062 patent/WO2008113358A1/fr active Application Filing
- 2008-03-14 KR KR1020097019519A patent/KR20090130000A/ko active IP Right Grant
- 2008-03-14 SI SI200830435T patent/SI2129377T1/sl unknown
- 2008-03-14 AT AT08715616T patent/ATE526966T1/de active
- 2008-03-14 JP JP2009553909A patent/JP5301474B2/ja not_active Expired - Fee Related
- 2008-03-14 BR BRPI0808820-9A patent/BRPI0808820A2/pt not_active IP Right Cessation
- 2008-03-14 CA CA2684592A patent/CA2684592C/fr not_active Expired - Fee Related
- 2008-03-14 EP EP11177654A patent/EP2388004A1/fr not_active Withdrawn
- 2008-03-14 NZ NZ579717A patent/NZ579717A/en not_active IP Right Cessation
- 2008-03-14 DK DK08715616.2T patent/DK2129377T3/da active
- 2008-03-14 PL PL08715616T patent/PL2129377T3/pl unknown
- 2008-03-14 US US12/527,907 patent/US20100105730A1/en not_active Abandoned
- 2008-03-14 MY MYPI20093675A patent/MY148695A/en unknown
- 2008-03-14 ES ES08715616T patent/ES2373275T3/es active Active
- 2008-03-14 AU AU2008228637A patent/AU2008228637B2/en not_active Ceased
- 2008-03-14 MX MX2009009388A patent/MX2009009388A/es active IP Right Grant
- 2008-03-14 EA EA200970869A patent/EA019695B1/ru not_active IP Right Cessation
- 2008-03-14 PT PT08715616T patent/PT2129377E/pt unknown
- 2008-03-14 EP EP08715616A patent/EP2129377B1/fr active Active
- 2008-03-19 CL CL200800797A patent/CL2008000797A1/es unknown
- 2008-03-19 AR ARP080101144A patent/AR065796A1/es unknown
-
2009
- 2009-09-15 IL IL200959A patent/IL200959A/en not_active IP Right Cessation
- 2009-09-16 CO CO09100112A patent/CO6220958A2/es not_active Application Discontinuation
-
2010
- 2010-08-03 HK HK10107411.4A patent/HK1140949A1/xx not_active IP Right Cessation
-
2011
- 2011-11-14 HR HR20110844T patent/HRP20110844T1/hr unknown
- 2011-12-02 CY CY20111101195T patent/CY1112285T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110844T1 (hr) | Tekući oblici soli 4-[2-(4-metilfenilsulfanil)fenil]piperidina | |
| HRP20140880T1 (hr) | Tekuä†a formulacija soli 1-/2-(2,4 dimetilfenilsulfanil)fenil/piperazina | |
| HRP20180098T1 (hr) | Kombinacije koje obuhvaćaju brekspiprazol ili jednu njegovu sol i jedan drugi lijek za uporabu u liječenju cns-poremećaja | |
| AR067772A1 (es) | Derivados piperazinicos de nicotinamida, medicamentos que los contienen, proceso para prepararlos y usos de los mismos para el tratamiento de trastornos asociados al sistema nervioso, cardiovascular y/o trastornos metabolicos. | |
| EA200801488A1 (ru) | Замещенные фенетиламины, обладающие серотонинергической и/или норэпинефринергической активностью | |
| RU2011120816A (ru) | Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов | |
| ECSP13012896A (es) | Derivados heterocíclicos de amina | |
| ECSP13013072A (es) | Derivados de pirazol | |
| AR063326A1 (es) | Aminometil-2-imidazoles, medicamentos que los contienen, metodo de preparacion, y usos para el tratamiento de trastornos asociados al sistema nervioso central | |
| AR059183A1 (es) | Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos | |
| Tajiri et al. | Serotonin 5-HT 7 receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| BRPI0905849A2 (pt) | Composto, composição farmacêutica e método | |
| CL2013003485A1 (es) | Compuestos derivados de benzamida sustituida como moduladores de receptores asociados con las aminas traza (taar1); composición farmacéutica; procedimiento de preparación; y uso en el tratamiento de depresión, psicosis, enfermedad de parkinson, ansiedad, trastorno de hiperactividad (adhd) y diabetes. | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
| HRP20120913T1 (hr) | Derivati 4-alkoksipiridazina kao brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| AR078958A1 (es) | Derivados de oxazolina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por los receptores taar1 | |
| EA201170352A1 (ru) | Способы лечения расстройств цнс | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| RU2006135654A (ru) | Способы модуляции глутаматных рецепторов для лечения нейропсихиатрических расстройств, включающие применение модуляторов сывороточных и индуцируемых глюкокортикоидами киназ | |
| ATE496026T1 (de) | 1,3-disubstituierte 4-methyl-1 h-pyrrol-2- carbonsäureamide und ihre verwendung zur herstellung von arzneimitteln | |
| FR2887335B1 (fr) | Procede pour la determination d'une contamination pathogene dans un fluide contenant des plaquettes sanguines | |
| AU2014363428B2 (en) | A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder | |
| PE20090720A1 (es) | Derivados de azaciclilbenzamida como antagonistas de histamina-3 | |
| Bonta | Schizophrenia, dissociative anaesthesia and near-death experience; three events meeting at the NMDA receptor |